PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1887018
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1887018
The global cardiology positron emission tomography (PET) scan market continues to expand as demand for advanced non-invasive cardiac diagnostic tools increases worldwide. According to the latest report, the global cardiology PET scan market size was valued at USD 1.91 billion in 2024, supported by rising cardiac disease prevalence, technological advancements in imaging systems, and greater adoption of precision diagnostics. The market is expected to reach USD 1.97 billion in 2025, reflecting steady growth driven by the rising geriatric population and increasing clinical preference for early and accurate cardiac evaluations. Looking ahead, the market is forecast to grow to USD 2.56 billion by 2032, exhibiting a CAGR of 3.8% from 2025 to 2032.
In 2024, North America dominated the global market with a 55.49% share, fueled by strong healthcare infrastructure, rapid adoption of hybrid PET/CT systems, and continual product approvals in the cardiac imaging domain.
Market Drivers
Technological Advancements Amplify Diagnostic Precision
The increasing introduction of advanced PET/CT and PET/MRI scanners is a key driver transforming cardiology PET imaging. Major players are heavily investing in AI-enabled imaging systems that offer superior accuracy, faster scan times, and enhanced visualization of myocardial perfusion, coronary flow reserve, and inflammation. These innovations strengthen clinical decision-making and support personalized treatment strategies.
A significant milestone was achieved in June 2024, when Siemens Healthineers launched its PET/CT scanner Biograph Trinion, featuring AI-driven workflows and integrated patient monitoring. Additionally, in September 2024, GE HealthCare received FDA approval for Flyrcado (flurpiridaz F 18), a next-generation PET MPI tracer for diagnosing Coronary Artery Disease (CAD). These advancements highlight the growing adoption of next-level cardiac imaging systems globally.
Market Restraints
High Equipment Costs and Shortage of Skilled Professionals
Despite its diagnostic significance, the market faces limitations due to the high cost of PET/CT systems, which ranges between USD 225,000 and USD 750,000, making these systems difficult to adopt in small and mid-sized healthcare settings.
Furthermore, the shortage of nuclear medicine professionals-including nuclear technologists, radiopharmaceutical specialists, and cardiac imaging physicians-remains a major challenge. Insufficient training opportunities and stringent regulatory requirements slow down widespread adoption, particularly in emerging markets.
Market Opportunities
Growing Demand for Advanced Imaging and Workflow Optimization
The rising global burden of cardiovascular diseases (CVDs) has heightened the demand for early diagnosis and improved treatment planning. This creates strong opportunities for manufacturers offering faster, high-resolution, and workflow-efficient imaging systems.
Partnerships between technology developers and diagnostic providers are accelerating market expansion. For example, IONETIX's partnership with Provision Diagnostic Imaging in February 2024 aims to improve radiotracer availability and reduce diagnostic turnaround times.
Market Challenges
Limited Radiotracer Availability
Radiotracer shortages remain a critical bottleneck for the global market, as many tracers require nearby cyclotron facilities due to their short half-life. In October 2024, the U.K.'s NHS reported severe radioisotope shortages that led to nationwide delays in cardiac imaging procedures. These supply chain fluctuations hinder consistent operations and limit the full utilization of high-value PET equipment.
Segmental Overview
By Source of Payment
The private health insurance/out-of-pocket segment dominated the market in 2024 due to faster approvals, wider provider choice, and personalized treatment packages.
The public segment is expected to witness moderate growth, supported by revised reimbursement proposals from regulatory agencies such as CMS.
By Service Provider
In 2024, hospitals held the largest market share, supported by advanced imaging infrastructure and availability of skilled staff.
Diagnostic centers are projected to grow at the fastest CAGR due to shorter waiting times, cost advantages, and increasing partnerships for PET/CT system procurement.
North America
North America led the market with USD 1.06 billion in 2024, driven by high CAD prevalence and strong investments in precision diagnostics. The U.S. remains the largest contributor, supported by continual product installations and PET/CT upgrades across hospitals and imaging networks.
Europe
Europe held a substantial market share in 2024, supported by healthcare digitalization initiatives and the presence of leading PET device manufacturers. Investments in diagnostic modernization continue to strengthen regional growth.
Asia Pacific
Asia Pacific is projected to record the highest CAGR during the forecast period due to rising healthcare investments, improved access to advanced imaging, and growing collaborations for radiopharmaceutical development.
Latin America & Middle East/Africa
Both regions are witnessing steady growth driven by increasing CVD incidence, rising healthcare spending, and gradual technology adoption.
Conclusion
With the market expanding from USD 1.91 billion in 2024 to USD 2.56 billion by 2032, the global cardiology PET scan market is poised for consistent growth. Advancements in imaging technologies, expanding diagnostic infrastructure, and rising cardiac disease prevalence will continue to shape the industry's future.
Segmentation By Source of Payment
By Service Provider
By Geography